Payload Information
General Information of This Payload
| Payload ID | PAY0BEHHA |
|||||
|---|---|---|---|---|---|---|
| Name | Maytansinoid derivative of batansine |
|||||
| Synonyms |
Maytansinoid derivative of batansine
Click to Show/Hide
|
|||||
| Target(s) | Microtubule (MT) | |||||
| Structure |
|
|||||
| Formula | C32H44ClN3O9 |
|||||
| Isosmiles | CN[C@@H](C)C(=O)O[C@H]1CC(=O)N(C)c2cc(cc(OC)c2Cl)C/C(C)=C/C=C/[C@H](OC)[C@@]2(O)C[C@H](OC(=O)N2)[C@H](C)[C@@H]2O[C@@]12C |
|||||
| InChI |
InChI=1S/C32H44ClN3O9/c1-17-10-9-11-24(42-8)32(40)16-23(43-30(39)35-32)18(2)28-31(4,45-28)25(44-29(38)19(3)34-5)15-26(37)36(6)21-13-20(12-17)14-22(41-7)27(21)33/h9-11,13-14,18-19,23-25,28,34,40H,12,15-16H2,1-8H3,(H,35,39)/b11-9+,17-10+/t18-,19-,23-,24-,25-,28-,31-,32-/m0/s1
|
|||||
| InChIKey |
ANHBJISROJTYCJ-QEUWLDAESA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
650.169 |
Polar area |
148.19 |
||
Complexity |
649.2766077 |
xlogp Value |
3.2755 |
|||
Heavy Count |
45 |
Rot Bonds |
5 |
|||
Hbond acc |
10 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
BAT8001 [Phase 3 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
41.40%
|
|||
| Patients Enrolled |
HER2-positive locally advanced or metastatic breast cancer.
|
||||
| Administration Dosage |
Patients received BAT8001 intravenously in a 21-day cycle, with dose escalation in 5 cohorts: 1.20, 2.40, 3.60, 4.80, and 6.00 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04189211 | Phase Status | Phase 1 | ||
| Clinical Description |
An open-label, dose escalation phase 1 clinical trial on safety, tolerability and pharmacokinetics of BAT8001 for injection in patients with HER2-positive solid tumors.
|
||||
| Primary Endpoint |
For BAT8001, 3.60 mg/kg was determined to be the MTD.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04185649 | Phase Status | Phase 3 | ||
| Clinical Description |
A clinical study evaluating the efficacy and safety of BAT8001 injection for the treatment of HER2-positive advanced breast cancer - a multicenter, randomized, open-label, positive-controlled, superiority phase 3 clinical trial in china.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04151329 | Phase Status | Phase 1/2 | ||
| Clinical Description |
Evaluation for the safety of BAT1306 and BAT8001 injection for the treatment of patients with HER2-positive advanced solid tumors phase 1/2a clinical trials of sexual, tolerability and pharmacokinetic characteristics.
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04189211 | Phase Status | Phase 1 | ||
| Clinical Description |
An open-label, dose escalation phase 1 clinical trial on safety, tolerability and pharmacokinetics of BAT8001 for injection in patients with HER2-positive solid tumors.
|
||||
BAT8003 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [5] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03884517 | Phase Status | Phase 1 | ||
| Clinical Description |
An open, escalating phase 1 clinical trial of BAT8003 (for injection) on the safety, tolerability and pharmacokinetics for patients with advanced epithelial cancer.
|
||||
References